DigmBio

DigmBio, founded in April 2020, is a leading biotechnology company dedicated to developing innovative drugs for unmet clinical areas such as cancer, neurodegenerative diseases, and fibrotic diseases. Its management team has decades of extensive experience in new drug development and global clinical trials. The company’s lead candidate drug, DM5167, is a second-generation selective PARP1 inhibitor. Preclinical study results indicate that DM5167, as a novel selective PARP1 inhibitor, demonstrates higher in vivo safety, shows high selectivity in enzymatic assays, and exhibits enhanced DNA trapping efficiency.